Anti-HER2 immunoliposomes for targeted drug delivery

Medicinal Chemistry Research

Volumn 8, Issue 7-8, 1998, Pages 383-391

  Park, J W ^a,e   Kirpotin, D ^b   Hong, K ^b   Colbern, G ^c,d   Shalaby, R ^b   Shao, Y ^b   Meyer, O ^b   Nielsen, U ^c   Marks, J ^c   Benz, C C ^a   Papahadjopoulos, D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALZA CORPORATION   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; NAVELBINE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; ENCAPSULATION; HUMAN; NONHUMAN; ONCOGENE NEU; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 0032432730     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Park, J. W., Hong, K., Kirpotin, D. B., Papahadjopoulos, D., and Benz, C. C. Immunoliposomes for cancer treatment, Adv. Pharmacology. 40: 399-435, 1997.
2. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy, Proc. Natl. Acad. Sci. USA. 88: 11460-11464, 1991.
3. Hynes, N. E. and Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer, Biochim. Biophys. Acta. 1198: 165-184, 1994.
4. Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Ullrich, A., and Slamon, D. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic, J. Clin. Immunol. 11: 117-127, 1991.
5. HER2 monoclonal antibody in patients with HER/neu-overexpressing metastatic breast cancer, J. Clin. Oncol. 14: 737-744, 1996.
6. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Paton, V., Shak, S., Lieberman, G., and Slamon, D. Efficacy and safety of HerceptinTM (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer, Proc. Amer. Soc. Clin. Oncol. 17: 97a, 1998.
7. Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Baselga, J., and Norton, L. Addition of HerceptinTM (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial, Proc. Amer. Soc. Clin. Oncol. 17: 98a, 1998.
8. Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., Wood, W. I., Papahadjopoulos, D., and Benz, C. C. Development of anti-p185HER2 immunoliposomes for cancer therapy, Proc. Natl. Acad. Sci. USA. 92: 1327-1331, 1995.
9. Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., LI, W. L., Carter, P., Benz, C. C., and Papahadjopoulos, D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cell in vitro., Biochemistry. 36: 66-75, 1997.
10. Carter, P., Rodrigues, M. L., Park, J. W., and Zapata, G. Preparation and uses of Fab' fragments from E. coli. In: H. H. R. McCafferty J, and Chiswell D J (ed.) Antibody Engineering: A Practical Approach, pp. 291-308. Oxford, UK: IRL Press, 1996.
11. Schier, R., Marks, J. D., Wolf, E. J., Apell, G., Wong, C., McCartney, J. E., Bookman, M. A., Huston, J. S., Houston, L. L., Weiner, L. M., and Adams, G. P. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library, Immunotechnology. 1: 73-81, 1995.
12. Kirpotin, D. B., Park, J. W., Hong, K., Shao, Y., Shalaby, R., Colbern, G., Benz, C. C., and Papahadjopoulos, D. Targeting of liposomes to solid tumors: the case of sterically stabilized anti-HER2 immunoliposomes, J. Liposome Research. 7: 391-417, 1997.
13. Huang, S. K., Lee, K. D., Hong, K., Friend, D. S., and Papahadjopoulos, D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice, Cancer Res. 52: 5135-5143, 1992.
14. Park, J. W., Kirpotin, D., Shalaby, R., Hong, K., Shao, Y., Marks, J., Papahadjopoulos, D., and Benz, C. C. Anti-HER2 immunoliposomes: significantly superior efficacy vs. doxorubicin, liposomal doxorubicin, and anti-her2 antibody treatment, via novel mechanism of action, Proc. Amer. Soc. Clin. Oncol. 17: 216a, 1998.
15. Demetzos, C., Kirpotin, D. B., and Papahadjopoulos, D. Preparation and properties of navelbine in sterically stabilized liposomes, Eur. J. Biopharmaceutics Pharmacokinetics. 21: 12-13, 1996.
16. Meyer, O., Kirpotin, D., Hong, K., Sternberg, B., Park, J. W., Woodle, M. C., and Papahadjopoulos, D. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides, J. Biol. Chem. 273: 15621-15627, 1998.
17. Park, J. W., Hong, K., Zheng, W., Benz, C. C., and Papahadjopoulos, D. Development of liposome- and anti-HER2 immunoliposome-plasmid complexes for gene delivery, Proc. Am. Assoc. Cancer Res. 38: 342, 1997.